InflaRx (IFRX)
(Delayed Data from NSDQ)
$1.43 USD
0.00 (0.00%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.43 0.00 (0.00%) 7:24 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
IFRX 1.43 0.00(0.00%)
Will IFRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IFRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IFRX
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
IFRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
Other News for IFRX
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
InflaRx’s Drug Shows Life-Saving Potential in COVID-19
InflaRx shares additional data, new analysis of PANAMO Phase III trial
InflaRx’s Promising Future: Buy Rating Reaffirmed Amidst Pipeline Progress and Upcoming R&D Insights
InflaRx Buy Rating: Strong Financials and High Potential of Gohibic for PG Treatment